Creative Medical Technology Holdings's quarterly market cap
declined
from Sep. 2025 ($8.59 Mil) to Dec. 2025 ($7.25 Mil) but then
increased
from Dec. 2025 ($7.25 Mil) to Mar. 2026 ($7.62 Mil).
Creative Medical Technology Holdings's annual market cap
declined
from Dec. 2023 ($6.33 Mil) to Dec. 2024 ($4.04 Mil) but then
increased
from Dec. 2024 ($4.04 Mil) to Dec. 2025 ($7.25 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Creative Medical Technology Holdings's Enterprise Value for Today is $-2.83 Mil.
Creative Medical Technology Holdings (NAS:CELZ) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Creative Medical Technology Holdings Market Cap Related Terms
Creative Medical Technology Holdings Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creative Medical Technology Holdings Market Cap Chart
For the Biotechnology subindustry, Creative Medical Technology Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creative Medical Technology Holdings Market Cap vs Biotechnology Industry
Creative Medical Technology Holdings Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creative Medical Technology Holdings (CELZ) has a Market Cap of $3.00 Mil as of Jun. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Creative Medical Technology Holdings and its competitors. According to the industry distribution chart, Creative Medical Technology Holdings ranks #1312 out of 1428 companies in the Biotechnology industry, placing it in the top 91.9%.
Is Creative Medical Technology Holdings' Market Cap too high?
Creative Medical Technology Holdings' current Market Cap is $3.00 Mil. The Biotechnology industry median Market Cap is 114.03. Creative Medical Technology Holdings' value of $3.00 Mil is 97.4% below this industry median. Based on the distribution chart, Creative Medical Technology Holdings ranks #1312 out of 1428 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Creative Medical Technology Holdings has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Creative Medical Technology Holdings' Market Cap compare to FBLG and GLMD?
According to the Biotechnology industry distribution chart, Creative Medical Technology Holdings ranks #1312 out of 1428 companies for Market Cap. This places Creative Medical Technology Holdings in the lower half of its industry. The industry median Market Cap is 114.03. Creative Medical Technology Holdings' value of $3.00 Mil is 97.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.03, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Creative Medical Technology Holdings's current Market Cap of $3.00 Mil is 97.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Creative Medical Technology Holdings and its competitors. For the Biotechnology industry, the median Market Cap is 114.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creative Medical Technology Holdings's current Market Cap is $3.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creative Medical Technology Holdings stock overvalued right now?
Based on GuruFocus' analysis, Creative Medical Technology Holdings (CELZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.32, compared to a current price of $0.81 — trading 153.2% above its estimated fair value. The current Market Cap is $3.00 Mil and 97.4% below the Biotechnology industry median of 114.03. Creative Medical Technology Holdings' overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Creative Medical Technology Holdings (CELZ), the current Market Cap is $3.00 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creative Medical Technology Holdings (CELZ) Overvalued in 2026?
Based on GuruFocus' analysis, Creative Medical Technology Holdings stock appears to be overvalued.
The current stock price of $0.81 is trading 153.2% above its estimated GF Value™ of $0.32.
GuruFocus considers Creative Medical Technology Holdings to be Significantly Overvalued.
Key valuation signals for CELZ:
Market Cap: $3.00 Mil
GF Value™: $0.32 vs. price of $0.81 (153.2% above fair value)
Industry Position: 97.4% below the Biotechnology median (#1312 of 1428)
No single metric tells the full story. See the CELZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creative Medical Technology Holdings Business Description
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
34GF Score
Get the complete analysis for CELZ
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CELZ has been successfully added to your 
